NCT06717334 A Study of Lung Cancer Screening in People With Unexplained Weight Loss
| NCT ID | NCT06717334 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Lung Cancer Screening |
| Study Type | OBSERVATIONAL |
| Enrollment | 409 participants |
| Start Date | 2024-12-02 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 409 participants in total. It began in 2024-12-02 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The researchers are doing this study to see if people with unexplained weight loss who have lung cancer screening are more likely to have or develop lung cancer than people without unexplained weight loss. The lung cancer screening will involve use of low-dose computed tomography (LDCT), a CT scan that gives off very low doses of radiation and can make detailed pictures of the lungs to help find tumors. The study researchers will also analyze participants' blood samples to determine if blood testing can be used to help to diagnose lung cancer.
Eligibility Criteria
Inclusion Criteria: * Eligible for American Cancer Society lung cancer screening, as follows as per the discretion of the screening team: * Age 50-80 years old * At least 20-pack year history of smoking * Weight loss of 3-10%, defined as UWL, within any timeframe over the past in the 18 months prior to enrollment, that cannot be attributed to an underlying medical condition at the discretion of the enrolling investigator * Note that patients who have 3-10% weight may still be enrolled if the enrolling investigator does not conclude that the weight loss can be attributed to the patient's intentional efforts. * Documented weight loss can be self-reported or extracted from weights obtained during physician visits. However, if self-reported weight loss is contradicted by weight loss documented in the medical record (e.g. a patients states that (s)he lost 10 lbs in the past 6 months, but a weight documented in the medical record does not support that history), the measured and quantified weight change will be used to ascertain eligibility * Life expectancy greater than 1 year, per assessment of the treating clinician. Exclusion Criteria: * Currently pregnant or trying to become pregnant via self-report * Prior history of recent CT scan of the chest either through LDCT screening or with a scan of the chest (standard, not LDCT) performed within the past 12 months * Prior history of NSCLC ○ Note that patients with a history of diagnosis of non-lung cancers are eligible for the study. * Currently undergoing or referred for diagnostic evaluation due to clinical suspicion for malignancy (e.g., referred to a medical or surgical oncologist, or scheduled for biopsy on the basis of a suspicious imaging abnormality). * Patients with a germline pathogenic genetic variant who have undergone whole body MRI within the past 12 months * Unable to comply with study procedures
Contact & Investigator
Alexis Chidi, MD, PhD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT06717334 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying Lung Cancer Screening. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06717334 currently recruiting?
Yes, NCT06717334 is actively recruiting participants. Contact the research team at chidia1@mskcc.org for enrollment information.
Where is the NCT06717334 trial being conducted?
This trial is being conducted at Basking Ridge, United States, Middletown, United States, Montvale, United States, Commack, United States and 4 additional locations.
Who is sponsoring the NCT06717334 clinical trial?
NCT06717334 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Alexis Chidi, MD, PhD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 409 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.